Central line-associated bloodstream infections
This article was originally published in The Gray Sheet
Executive Summary
Incidents are down an estimated 18% from predicted levels nationally, according to a May 27 report from the Centers for Disease Control and Prevention. CDC's "First State-Specific Healthcare-Associated Infections Summary Data Report" looked at central line-associated bloodstream infections (CLABSI) because states most frequently mandate reporting as part of the National Healthcare Safety Network, the CDC-sponsored framework through which hospitals are pursuing efforts to reduce infection rates. The 1report notes 4,615 CLABSIs were reported from January 2009 through June 2009 at 1,538 facilities nationally
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.